Strategic partnerships Epidarex is a transatlantic venture capital firm actively co-investing with leading funds and corporates (Roche Venture Fund, Sofinnova Partners, BioGeneration Ventures, University of Strathclyde, Pfizer Ventures). This presents opportunities to position solution offerings as potential co-investment or portfolio support aligned with their life sciences focus.

Early stage focus With emphasis on early-stage, high-growth life science opportunities and building companies from scratch, Epidarex could be receptive to technologies that fill unmet medical needs and accelerate go-to-market paths, especially in under-ventured markets.

Portfolio expansion Recent funding activity across multiple portfolio companies (Mironid, Curvetx, Leucid Bio) indicates a willingness to deploy capital across diverse modalities (biotech, cell therapy, mRNA-targeted therapies), signaling openness to new partnerships that complement existing investments.

Leadership refresh New Managing Partners appointed in 2026 (Elizabeth Roper, Peter Finan) alongside co-founder Sinclair Dunlop suggest a strategic growth phase and openness to entering new deals, collaborations, and advisory relationships under refreshed leadership.

Market positioning As a cross-border life sciences fund investing in under-ventured markets, Epidarex may value technologies that enable scalable, patient-benefiting solutions with clear regulatory and reimbursement pathways, offering partners avenues to co-create market-ready assets.